Literature DB >> 3244604

Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques.

T Sato1, M Kanke, H G Schroeder, P P DeLuca.   

Abstract

Microspheres containing methylene blue and prednisolone acetate were prepared by one of three methods: freeze-drying, evaporation, and solvent-extraction-precipitation. An extremely porous structure was obtained by the freeze-dry and solvent-extraction-precipitation procedures. The specific surface area of 6.33-microns particles was 20.6 m2/g, or 35 times that of a particle devoid of pores, and the void space was 59-61%. The sphericity, size, and yields of the microspheres were influenced by the preparation procedure, surfactant type and concentration, temperature of the continuous phase, polymer concentration in the dispersed phase, and ratio of marker to polymer. The most suitable processing conditions were a polymer concentration of 5-10%, a marker loading of 10%, 0.1% sorbitan sesquioleate as the surfactant, and temperature adjustment of the continuous phase from 15 to 50 degrees C following the addition of the dispersed phase. Complete release of the highly water soluble methylene blue occurred within 72 hr, while the less soluble prednisolone acetate released much more slowly, i.e., 90% after 7 days. The microspheres remained relatively intact during the in vitro release of methylene blue, confirming that the incorporated agent was confined to the walls of the porous network. Collapse of the polymer structure was evident after 7 days. The release therefore was believed to be governed principally by the solubility of the drug and the porosity of the matrix.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3244604     DOI: 10.1023/a:1015855210319

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Effects of entrapment in liposomes on the distribution, degradation and effectiveness of methotrexate in vivo.

Authors:  H K Kimelberg; M L Atchison
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

2.  Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy.

Authors:  R L Juliano; D Stamp; N McCullough
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

3.  Serum albumin beads: an injectable, biodegradable system for the sustained release of drugs.

Authors:  T K Lee; T D Sokoloski; G P Royer
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

4.  Liposomes as drug carriers.

Authors:  J H Fendler; A Romero
Journal:  Life Sci       Date:  1977-04-01       Impact factor: 5.037

5.  Influence of physicochemical properties of polylactic acid on the characteristics and in vitro release patterns of polylactic acid microspheres containing local anesthetics.

Authors:  N Wakiyama; K Juni; M Nakano
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-07       Impact factor: 1.645

6.  Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration.

Authors:  K Hirano; C A Hunt
Journal:  J Pharm Sci       Date:  1985-09       Impact factor: 3.534

7.  Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres.

Authors:  L M Sanders; J S Kent; G I McRae; B H Vickery; T R Tice; D H Lewis
Journal:  J Pharm Sci       Date:  1984-09       Impact factor: 3.534

8.  Characterization of drug-loaded poly(d,l-lactide) microspheres.

Authors:  S Benita; J P Benoit; F Puisieux; C Thies
Journal:  J Pharm Sci       Date:  1984-12       Impact factor: 3.534

  8 in total
  16 in total

1.  In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.

Authors:  Byung Ho Woo; Kyu-Heum Na; Bhas A Dani; Ge Jiang; B C Thanoo; Patrick P DeLuca
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

2.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

Authors:  P O'Hara; A J Hickey
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

3.  Microencapsulation of solid dispersions: release of griseofulvin from griseofulvin:phospholipid coprecipitates in microspheres.

Authors:  G K Vudathala; J A Rogers
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

4.  Encapsulation of water-insoluble drug by a cross-linking technique: effect of process and formulation variables on encapsulation efficiency, particle size, and in vitro dissolution rate.

Authors:  Pralhad T Tayade; Rajendrakumar D Kale
Journal:  AAPS PharmSci       Date:  2004-03-22

5.  Two-stage optimization process for formulation of chitosan microspheres.

Authors:  Rajesh R Dubey; Rajesh H Parikh
Journal:  AAPS PharmSciTech       Date:  2004-02-06       Impact factor: 3.246

6.  Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation.

Authors:  F X Lacasse; P Hildgen; J Pérodin; E Escher; N C Phillips; J N McMullen
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

7.  Production of 5-15 microns diameter alginate-polylysine microcapsules by an air-atomization technique.

Authors:  K K Kwok; M J Groves; D J Burgess
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

8.  Taxol encapsulation in poly(epsilon-caprolactone) microspheres.

Authors:  S K Dordunoo; J K Jackson; L A Arsenault; A M Oktaba; W L Hunter; H M Burt
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Poly(D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: optimization of process parameters.

Authors:  Rajesh H Parikh; Jolly R Parikh; Rajesh R Dubey; Heena N Soni; Kishor N Kapadia
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

10.  Polyglycolide: degradation and drug release. Part II: drug release.

Authors:  S Hurrell; R E Cameron
Journal:  J Mater Sci Mater Med       Date:  2001-09       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.